It has been recently observed that the presence of IgM antibodies against CD64 in the blood of MS patients seems to be associated with a significantly lower annualized relapse rate and with the improved maintenance of clinical stability compared to patients without these antibodies [34]. This evidence concerns the gene FCGR1A and myeloid sarcoma.